Levosimendan Tillomed

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Tillomed (Levosimendan)

Q: What is Levosimendan Tillomed used for?

Levosimendan Tillomed is an intravenous calcium‑sensitising inotrope indicated for the short‑term treatment of acute decompensated heart failure and cardiogenic shock in adult patients who require rapid improvement in cardiac output.

Q: How does levosimendan work?

Levosimendan binds to troponin C, increasing its sensitivity to calcium and thereby enhancing myocardial contractility without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing cardiac after‑load.

Q: What is the usual dose of levosimendan?

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and haemodynamic parameters. Typical protocols involve a loading dose followed by a continuous infusion, but exact amounts are individualized.

Q: Is levosimendan safe in pregnancy or breastfeeding?

Safety data for levosimendan during pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it should be used only if the potential benefit justifies the potential risk to the fetus or infant.

Q: How do I order Levosimendan Tillomed from GNH India?

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Q: How does levosimendan compare with other inotropes such as dobutamine?

Unlike catecholamine inotropes like dobutamine, levosimendan increases contractility by calcium sensitisation rather than raising intracellular calcium, which may result in fewer arrhythmogenic effects. It also provides vasodilation through potassium‑channel activation, offering combined inotropic and after‑load‑reducing benefits.

Q: How should Levosimendan Tillomed be stored and handled?

Levosimendan Tillomed must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Use aseptic technique when preparing the infusion and discard any solution that appears discoloured or particulate.

Q: How is Levosimendan administered?

Levosimendan is given intravenously, usually as an initial loading infusion followed by a continuous maintenance infusion over several hours. Administration is performed in a monitored setting such as an intensive care unit or cardiac care unit.

Q: What are the most serious risks to watch for when using levosimendan?

The most serious risks include severe hypotension, life‑threatening ventricular arrhythmias, myocardial ischaemia, and rare anaphylactic reactions. Continuous haemodynamic and ECG monitoring is essential throughout the infusion.

Q: Who should not use levosimendan?

Levosimendan should be avoided in patients with uncontrolled severe hypotension, mechanical obstruction of the outflow tract, known hypersensitivity to the drug, or in those where the risk of arrhythmia outweighs potential benefit. Clinical judgment is required for each individual case.

Levosimendan, the active ingredient in Levosimendan Tillomed, is a calcium sensitizer presented as a intravenous solution for intravenous use. It treats acute decompensated heart failure and cardiogenic shock in hospitalized adults.

GNH India supplies Levosimendan Tillomed as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Manufacturer / TM Owner

Tillomed Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is an inotropic agent used in severe cardiac conditions where contractility is compromised.

Acute decompensated heart failure: improves cardiac output and relieves congestion.
Cardiogenic shock: stabilises haemodynamics and supports organ perfusion.
Advanced chronic heart failure (intermittent infusion): provides temporary haemodynamic support during worsening episodes.

How It Works

Levosimendan increases cardiac contractility by binding to troponin C and sensitising it to calcium, enhancing the force of myocardial contraction without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing after‑load, which together improve cardiac output in heart failure.

Side Effects

Levosimendan may cause a range of adverse reactions, from mild to severe.

Common Side Effects

Headache: mild to moderate intensity.
Hypotension: transient drop in blood pressure.
Nausea: occasional gastrointestinal upset.
Tachycardia: increase in heart rate.
Arrhythmias: non‑sustained ventricular ectopy.
Flushing: transient skin reddening.

Serious or Rare Side Effects

Severe hypotension: may require vasopressor support.
Ventricular tachycardia or fibrillation: life‑threatening rhythm disturbances.
Myocardial ischaemia: chest pain or ECG changes.
Anaphylactic reaction: rare but possible hypersensitivity.
Pulmonary oedema worsening: in patients with fluid overload.
Liver enzyme elevation: transient hepatic dysfunction.

Precautions & Warnings

Levosimendan requires careful monitoring and specific safety measures before and during therapy.

Blood pressure monitoring: watch for hypotension and adjust infusion rate.
Cardiac rhythm surveillance: detect arrhythmias early.
Dose adjustment: consider renal or hepatic impairment when setting infusion parameters.
Contraindication in severe hypotension: avoid use when systolic BP is <90 mmHg.
Caution with mechanical obstruction: do not use in patients with outflow tract obstruction.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

Concurrent vasodilators (e.g., nitroglycerin): may cause profound hypotension.
Strong CYP3A4 inhibitors (e.g., ketoconazole): increase levosimendan plasma concentrations.
Other inotropes (e.g., dobutamine): additive risk of arrhythmias.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may blunt the positive inotropic effect.
Diuretics: can exacerbate volume depletion and hypotension.
ACE inhibitors or ARBs: may enhance hypotensive response.

Frequently Asked Questions

Levosimendan Tillomed is an intravenous calcium‑sensitising inotrope indicated for the short‑term treatment of acute decompensated heart failure and cardiogenic shock in adult patients who require rapid improvement in cardiac output.

Levosimendan binds to troponin C, increasing its sensitivity to calcium and thereby enhancing myocardial contractility without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing cardiac after‑load.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s clinical status, weight, and haemodynamic parameters. Typical protocols involve a loading dose followed by a continuous infusion, but exact amounts are individualized.

Safety data for levosimendan during pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it should be used only if the potential benefit justifies the potential risk to the fetus or infant.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Unlike catecholamine inotropes like dobutamine, levosimendan increases contractility by calcium sensitisation rather than raising intracellular calcium, which may result in fewer arrhythmogenic effects. It also provides vasodilation through potassium‑channel activation, offering combined inotropic and after‑load‑reducing benefits.

Levosimendan Tillomed must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Use aseptic technique when preparing the infusion and discard any solution that appears discoloured or particulate.

Levosimendan is given intravenously, usually as an initial loading infusion followed by a continuous maintenance infusion over several hours. Administration is performed in a monitored setting such as an intensive care unit or cardiac care unit.

The most serious risks include severe hypotension, life‑threatening ventricular arrhythmias, myocardial ischaemia, and rare anaphylactic reactions. Continuous haemodynamic and ECG monitoring is essential throughout the infusion.

Levosimendan should be avoided in patients with uncontrolled severe hypotension, mechanical obstruction of the outflow tract, known hypersensitivity to the drug, or in those where the risk of arrhythmia outweighs potential benefit. Clinical judgment is required for each individual case.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.